Champions Oncology (NASDAQ:CSBR) Posts Earnings Results, Beats Estimates By $0.06 EPS

Champions Oncology (NASDAQ:CSBR) issued its quarterly earnings results on Thursday. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06, FiscalAI reports. The company had revenue of $15.23 million during the quarter, compared to the consensus estimate of $15.04 million. Champions Oncology had a negative net margin of 1.87% and a negative return on equity of 27.48%.

Here are the key takeaways from Champions Oncology’s conference call:

• Revenue and profitability improved: First-quarter revenue rose 9% year over year to $15.2 million, gross margin increased to 50% from 43%, and adjusted EBITDA reached $671,000 versus $59,000 a year ago—marking the fifth consecutive quarter of positive adjusted EBITDA.
• Translational oncology services revenue was $14.3 million, with margins benefiting from lower third-party radiolabeling costs after bringing capabilities in-house and from operating leverage.
• Data licensing momentum accelerated: Data revenue reached $893,000, exceeding the total generated in all of fiscal 2026, supported by a broader customer base and a robust pipeline. Management cautioned that licensing revenue will remain lumpy because contracts close on varying timelines.
• Management remains encouraged by discussions with venture groups and potential pharmaceutical partners regarding Corellia AI, but provided no timing for outside funding or a licensing deal. Any such proceeds could be redirected toward data initiatives, other growth projects, and the bottom line.
• The company used approximately $500,000 of cash during the quarter and ended with $4.4 million of cash and no debt. Sales and marketing expenses rose to $3.0 million from $1.8 million as Champions works to generate returns from its expanded commercial organization.

Champions Oncology Stock Up 1.8%

Shares of Champions Oncology stock traded up $0.09 during trading hours on Thursday, hitting $5.10. 14,427 shares of the company’s stock traded hands, compared to its average volume of 8,389. The stock has a 50 day simple moving average of $5.44 and a 200-day simple moving average of $5.82. The company has a market cap of $70.99 million, a PE ratio of -63.75 and a beta of 0.40. Champions Oncology has a twelve month low of $4.83 and a twelve month high of $8.74.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut Champions Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Hedge Funds Weigh In On Champions Oncology

A number of hedge funds have recently added to or reduced their stakes in the business. Mink Brook Asset Management LLC purchased a new stake in shares of Champions Oncology during the fourth quarter valued at $555,000. Goldman Sachs Group Inc. acquired a new stake in Champions Oncology in the first quarter valued at approximately $201,000. Jane Street Group LLC bought a new stake in Champions Oncology in the first quarter worth $200,000. Essex Investment Management Co. LLC acquired a new position in shares of Champions Oncology during the 4th quarter valued at about $126,000. Finally, XTX Topco Ltd bought a new position in Champions Oncology in the 2nd quarter worth $103,000. Institutional investors and hedge funds own 41.30% of the company’s stock.

About Champions Oncology

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.